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Abstract Even though the etiology of Alzheimer’s disease
(AD) remains unknown, it is suggested that an interplay
among genetic, epigenetic and environmental factors is
involved. An increasing body of evidence pinpoints that
dysregulation in the epigenetic machinery plays a role in
AD. Recent developments in genomic technologies have
allowed for high throughput interrogation of the epigen-
ome, and epigenome-wide association studies have already
identified unique epigenetic signatures for AD in the cor-
tex. Considerable evidence suggests that early
dysregulation in the brainstem, more specifically in the
raphe nuclei and the locus coeruleus, accounts for the most
incipient, non-cognitive symptomatology, indicating a
potential causal relationship with the pathogenesis of AD.
Here we review the advancements in epigenomic tech-
nologies and their application to the AD research field,
particularly with relevance to the brainstem. In this respect,
we propose the assessment of epigenetic signatures in the
brainstem as the cornerstone of interrogating causality in
AD. Understanding how epigenetic dysregulation in the
brainstem contributes to AD susceptibility could be of
pivotal importance for understanding the etiology of the
disease and for the development of novel diagnostic and
therapeutic strategies.
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Introduction
Alzheimer’s disease (AD) is a chronic, neurodegenerative
disorder that currently accounts for 60–80 % of dementia
cases [1, 2]. The prevalence of AD is expected to increase
dramatically with the exponential increase in the aging
population and a lack of effective therapeutic options.
Recent evidence suggests that the incipient stages of the
disease may start in young adulthood where they remain
asymptomatic until advanced age [3, 4]. Throughout its
progression, AD deprives patients of their quality of life,
by negatively impacting upon emotional control, cognition,
memory, and language skills, converting them to highly
dependent reflections of their past selves, and substantially
decreasing their life expectancy. The pathogenesis of AD is
associated with amyloid beta (Ab) plaques, which form
degradation-resistant aggregates, and hyperphosphorylated
tau protein that leads to the formation of intraneuronal
neurofibrillary tangles (NFTs) [2, 5]. These two charac-
teristic hallmarks are believed to lead to synaptic
dysfunction and eventually neuronal cell loss, causing
dramatic cortical and subcortical atrophy [6–9]. While the
hypotheses about the preliminary appearance of one of the
two hallmarks are raging, a definite mechanism has yet to
be provided (i.e. [8, 10]). To date, the Ab burden has
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mainly been associated with the neurobiological under-
pinning of AD, whereas tau pathology is positively
correlated with the progression of cognitive deterioration in
the patients [3, 10, 11].
In AD, individual disease risk is determined by genetic
and environmental factors, as well as complex interactions
between them. From a genetic perspective AD can be
classified into two subtypes, familial or sporadic, and while
the symptomatology and the progression of both forms are
comparable, the etiology is fundamentally different [12].
Familial AD accounts for only 5–10 % of the disease cases
and is related to the existence of genetic mutations in
specific genes, such as those encoding amyloid precursor
protein (APP) and presenilin (PSEN) 1 (PSEN1) and
PSEN2 [13–20], which are all involved in the production of
Ab. Sporadic AD is the most prevalent form of AD, usually
occurs later in life ([65 years) and bares non-Mendelian
traits. In recent years, common genetic variants have been
robustly associated with sporadic AD via genome-wide
association studies (GWAS) and subsequent meta-analyses
([21]; for specific GWAS results see [22–26]), although
these only account for a third of disease susceptibility risk
[21]. Therefore, more recent research efforts have focused
on a potential role for epigenetic mechanisms in disease
etiology [27].
To date, even though there is a strong association
between hallmark appearance and the incidence of AD, the
pathogenesis of the disease remains uncertain. Moreover,
evidence has shown that some individuals may carry the
most salient genetic risk factors for AD and also express
profuse Ab and tau pathology, but yet never develop the
disorder [17, 28–30]. Strikingly, even monozygotic twins
can have discordant AD outcomes [29], and as such it has
been suggested that these phenomena could be explained
by epigenetic mechanisms [27]. The epigenetic machinery
induces reversible changes in gene expression via covalent
interactions with mainly the chromatin components. These
modifications in gene activity, while ever-changing, are
more pronounced during development and remain more
stable in differentiated cell types. Hence, normal dynamic
changes in the epigenetic machinery are responsible for
cellular development and differentiation, but also for
transiently imprinting environmental, behavioral as well as
social effects on gene expression, maintaining genomic
homeostasis throughout the lifespan. The umbrella term,
epigenetic modifications, covers a gamut of mechanisms,
namely DNA modifications [5-methylcytosine (5-mC),
5-hydroxymethylcytosine (5-hmC), 5-formylcytosine (5-
fC), and 5-carboxylcytosine (5-caC)], chromatin remodel-
ing by means of remodeling complexes and post-
translational histone modifications, and non-coding RNA
[ncRNAs; long ncRNA (lncRNA), short ncRNA
(sncRNA)]. Currently, the best-characterized epigenetic
modifications are DNA modifications, with DNA methy-
lation within CpG islands being the most extensively
studied. Contrary to popular belief, DNA methylation is
not solely associated with gene repression, but the differ-
ential effect on gene activity depends on the location of the
epigenetic modification on the gene or its proximity [31].
Additionally, the newly characterized DNA modifications,
5-hmC, 5-fC, 5-caC, were originally thought to be transient
marks in the demethylation pathway; however, recent
evidence suggests that 5-hmC may represent an indepen-
dent epigenetic mark and has been associated with active
gene transcription [32]. In AD, recent epigenome-wide
association studies (EWAS) have identified robust changes
in DNA methylation patterns in specific genes; yet whether
this remains a cause or a consequence of the disease is not
currently known.
This review provides a thorough update on the fast-
pacing advancements in (epi)genomic technology with a
main focus on its application to AD-related research.
Moreover, by reviewing recent evidence on the early
involvement of the brainstem in the non-cognitive early
symptomatology of the disease, it discusses the need to
systematically assess epigenetic dysregulation in this brain
region to identify novel dysfunctional pathways. Ulti-
mately, this review aims to raise critical questions of
temporal and spatial causality of AD pathogenesis and how
the answer may be found in innovative brain structure
targets with the assistance of state-of-the-art genomic
technology.
Epigenomic technology advancements in AD
Over the past decade, the number of publications investi-
gating the role of epigenetic mechanisms in AD has
dramatically increased, which have substantially con-
tributed to our understanding of the disease (reviewed by
Lardenoije et al. [17]). Major advances in genomic tech-
nology have helped overcome numerous hurdles that were
faced in the early years of neuroepigenetic studies [27].
Such caveats involved the limited available techniques, the
specificity and reliability of the epigenetic methodology
used, as well as issues concerning genomic coverage, tissue
cell-type composition, and sample sizes.
Towards genome-wide sequencing of the AD brain
It is evident that genomic studies in AD have now pro-
gressed from restricted, targeted antibody-based techniques
to genome-wide arrays and sequencing technology with
single CpG site resolution. In 1995, the first empirical
studies in AD used methylation-specific restriction
enzymes and Southern Blot technique demonstrated
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hypomethylation in the APP gene promoter region [33].
Since then, several approaches have emerged, involving
immunohistochemistry, methylation-specific polymerase
chain reaction (PCR), bisulfite (BS) conversion, high per-
formance liquid chromatography (HPLC), pyrosequencing
and various methylation assays [34]. The imperative need
for more concise and collective results shifted epigenetic
research in AD to more systematic genome-wide approa-
ches. In 2012, Baluski and colleagues were the first to
utilize Illumina microarray technology, Infinium
HumanMethylation27 Beadchip assay, enabling quantifi-
cation of DNA methylation at [27,000 CpG sites, and
detected AD-associated DNA methylation differences in
the prefrontal cortex of late-onset sporadic AD patients in
comparison to cognitively normal controls [35]. More
recently, studies have employed the more extensive, cur-
rent workhorse for epigenetic studies, the Infinium
HumanMethylation450 BeadChip assay (450K), detecting
[485,000 methylation sites at a single nucleotide resolu-
tion, covering approximately 1.5 % of total genomic CpG
sites, mainly amidst promoter regions [26, 36–39]. The first
two large-scale EWAS in AD identified overlapping dif-
ferentially methylated CpG loci, namely ANK1, RPL13,
CDH23, and RHBDF2 [40]. This year, a further Illumina
Infinium microarray (Illumina MethylationEPIC Beadar-
ray) was launched, covering [850,000 CpG sites [41],
although it has yet to be utilized in AD. The continuous
advancements in microarray technology, combined with
their cost effectiveness have made this approach the most
widely utilized EWAS method in large sample cohort
studies. However, such methodologies only cover a small
percentage of CpG sites and thus whole-genome sequenc-
ing techniques remain the best option for in-depth genome-
wide examination. Only recently, the first whole-genome
bisulfite sequencing (WGBS) was conducted with much
wider coverage than just the promoter proximal CpGs
(20 % of total genomic CpG sites) [42]. In addition, the
first low(er)-cost deep sequencing reduced representation
bisulfite sequencing (RRBS) kit recently became available
with a high coverage of up to 4,000,000 CpGs in human
samples [43], and as such the use if these technologies in
AD tissue is anticipated.
Beyond DNA and CpG specific methylation
Epigenomic studies have been largely focused on DNA
(cytosine) methylation, overlooking additional epigenetic
signatures. To date, further methodological improvements
have allowed the detection of demethylation marks (5-
hmC, 5-fC, 5-caC), post-translational histone modifications
as well as deregulated ncRNAs. New advancements have
allowed the discrimination of 5-hmC and 5-fC by
employing oxidative bisulfite sequencing (oxBS-Seq) and
reduced bisulfite sequencing (redBS-Seq), respectively
[44–47]. More recently, researchers have made use of this
chemistry and coupled it with the 450K array, presenting
the oxBS-450K method [48]. This method was used suc-
cessfully to identify differential DNA hydroxymethylation
patters across different anatomical region of the human
brain but also and most importantly to accurately quantify
‘‘true’’ methylation levels that up until now were con-
founded by hydroxymethylation levels [49]. Application of
oxBS-arrays or oxBS sequencing on human AD samples
will hopefully not only highlight the importance of DNA
demethylation in cognitive processes but also confirm the
hypothesized crucial role of 5-hmC in AD as hinted by
immunohistochemical studies [50–53] (reviewed in [54]).
Whilst for the DNA modifications 5-fC and 5-caC, there
are currently only two studies examining their levels in AD
with disparate results; Condliffe et al. [51] did not detect
AD-associated differences, whereas Bradley-Whitman
et al. reported a decrease in the hippocampal area in pre-
clinical AD samples [55]. Therefore, studies using redBS-
Seq or comparable techniques will elucidate the levels of
these modifications in AD at single nucleotide resolution.
While traditional epigenetic research has focused on
methylation of a cytosine within a CpG dinucleotide, lar-
gely within CpG islands, more recent studies have begun
examining intermediate/low CG-content regions as well as
non-CpG DNA methylation. An increasing number of
targeted AD studies nowadays examine the methylation
status of more than just CpG-rich gene promoter areas [38].
The newly developed WGBS method provides adequate
information about intergenic CpGs distal to gene promoters
as well as non-CpG methylation [42]. Thus, it is expected
that implementation of this technique in AD studies will
contribute to a deeper understanding of DNA methylation
to the pathophysiology and will highlight further regions
on the genome that display differential DNA methylation
in disease.
Although genome-wide histone modification analysis
using chromatin immunoprecipitation (ChIP) techniques
are available, to date no studies have used this approach in
AD. In fact, only three published studies have directly
connected histone modifications to AD. Zhang and col-
leagues found downregulated H3K18 and H3K23
acetylation when comparing temporal lobe samples from
AD patients to those of controls using monitoring liquid
chromatography-mass spectrometry [56]. Mastroeni and
colleagues immunohistochemically detected aberrant
extra-nuclear localization of H3K4 tri-methylation at the
most incipient stages of the disease [57]. Whilst, Graff and
colleagues detected increase in the protein levels of histone
deacetylase 2 (HDAC2) in AD brains [58]. Finally, while
micro-RNAs (miRNAs) are very well studied with targeted
and genome-wide array-based methods, other ncRNAs
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have been generally understudied. Recently, though AD-
associated lncRNAs have been identified for the first time
by re-annotating previously probed uniquely mapped
lncRNAs [59]. Among the most significantly dysregulated
lncRNAs were n341006 and n336934, lncRNAs involved
in protein ubiquitination and cholesterol homeostasis,
respectively [59].
Cross regional and blood differences in epigenetic
modifications
One caveat when examining epigenetic as opposed to
genetic variation is the need to investigate changes in a
tissue-specific manner. To date, studies have largely uti-
lized tissue from various cortical regions given that these
are the site of neurodegeneration and dysfunction observed
with advanced progression of the disease (hippocampus,
frontal cortex dorsolateral prefrontal cortex, the entorhinal
cortex, the superior temporal cortex, the medio-temporal
gyrus, the superior temporal gyrus), although a handful
have also included the cerebellum [36–38, 51]. The use of
cerebellum is rather interesting in such studies as it is rel-
atively spared from AD pathology, even at the late stages of
the disease, and thus serves as an internal control tissue.
The investigation of tissue-specific epigenetic signatures
in the brain allows the elucidation of the underlying
mechanisms in the pathophysiology of AD, whilst interro-
gation of epigenetic variation in the blood is of pivotal
importance to develop novel molecular biomarkers for the
early diagnosis of AD. To date only a handful of studies
have investigated DNA methylation changes in blood from
AD patients; D’Addario’s team showed global DNA
hypermethylation in blood samples of sporadic AD patients,
while Lunnon et al. detected DNA methylation differences
at specific loci in ante-mortem blood samples from sporadic
AD patients [37, 66]. Altogether, these results encourage
further research to identify AD-related epigenetic signa-
tures as biomarkers in larger sample cohorts.
Cell-specific epigenetic changes
While the identification of AD-related epigenetic changes
in post-mortem brain tissue is highly important for a better
understanding of the pathophysiology, the cellular hetero-
geneity constitutes a major caveat in interpreting the
results. It is well described in the literature that AD-related
neurodegeneration is highly specific towards selected
neuronal cell types and is also accompanied by glial acti-
vation, which could confound the interpretation of
epigenetic studies on brain tissue in AD. Steps to specify
cell type composition can be taken in early experimental
stages with a range of methods available to isolate specific
cell types. Such methods involve density gradients, laser
capture microdissection (LCM), fluorescent-activated cell
sorting (FACS), magnetic affinity cell sorting (MACS) and,
more recently, isolation of nuclei tagged in specific cell
types (INTACT) [60, 61]. The INTACT method is
specifically adapted for interrogating epigenetic marks
ranging from DNA methylation to histone modifications by
means of selectively capturing nuclei that express an
antibody-tagged protein [60]. Hence, its application will be
very fruitful for unravelling neuron or glial specific AD-
related epigenetic signatures. LCM has recently been
employed for the characterization of amyloid plaques [62]
as well as gene expression via RNA sequencing comparing
AD and control brain tissue [63]. Encouraging data from
the latter study imply that LCM could be used for specific
cell type isolation in epigenetic studies, since it does not
appear to induce disease-unrelated transcriptional changes.
Interesting applications of this methodology would be not
only targeting the epigenetic profiling of neurons either in
the vicinity of AD hallmarks (namely gliosis and amyloid
plaques), or severely affected by tau pathology, but also
assessing the differential epigenetic signatures of AD
pathology spared neurons. Finally, in already collected
datasets on unsorted tissue, bioinformatic analyses can also
correct for neuronal/glia composition utilizing published
algorithms [64]. This approach has already been used in the
analysis of 450K array data generated in AD tissue
enabling the researchers to control for cellular hetero-
geneity bias [37, 38].
Sample size caveat; loophole through validation
cohorts?
Regardless of the technological improvements that have
assisted a deeper investigation of the epigenetic machinery
in AD, there is still one caveat that persists; the sample size
of the cohorts used. To date, there is a circumscribed
amount of EWAS studies on AD [35–38, 65, 66], and only
two of them have a sample size exceeding 100 [36, 37]. A
fortunate phenomenon in the limited number of EWAS
studies in AD, performed to date, is that a considerable
number of epigenetic alterations have a replicable effect in
independent cohorts from other studies (i.e. finding from
[37] have been replicated by [36, 38]). The falling cost of
whole-genome studies in combination with the exponential
increase in high quality brain tissue available from brain
banks worldwide will probably reinforce studies with lar-
ger sample size. Nevertheless, one should be cautious with
the predilection of tissue from AD patients. It was recently
suggested that DNA methylation profiles of various neu-
rodegenerative disorders, including AD, involve similar
early epigenetic-associated pathogenic mechanisms, which,
over time evolve into divergent clinical cases with distinct
molecular and cellular underpinnings [65]. This concept
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was also supported by the latent early life associated reg-
ulation (LEARn) model of Lahiri and colleagues which
proposes that neurobiological disorders share a similar
mechanistic etiology [67]. More specifically, according to
this hypothesis, early life stressors modify the expression
levels of disorder-associated genes, a change that is tran-
siently maintained by epigenetic mechanisms and is shared
among a wider spectrum of neurobiological disorders. The
differential expression of these genes remains within
physiological range, until, later in life, multiple ‘‘hits’’, i.e.
environmental agents, dietary factors, and lifestyle habits,
accumulate, leading to aberrant-pathological changes in
expression [67, 68]. Evidently, these notions should be
taken into consideration for longitudinal studies in popu-
lations at high risk of developing AD [69]. Furthermore,
research on incipient stages of AD might not be in conflict
with other confounding factors, but as the pathology
worsens, the epigenome seems to change dramatically.
Moreover, recent evidence showed that once proper
bioinformatic analysis is employed, i.e. correcting not only
for technical issues and sex, but also for common neu-
ropathologies seen in the elderly population—the total
number of age-dependent CpG methylation profiles is
reduced by approximately 40 % [70]. Therefore, large
sample sizes with a thorough medical history of medica-
tion, information on concurrent neuropathologies as well as
epigenetic-modifying environmental exposures, together
with the reciprocal advances in bioinformatic analysis
tools, would hone current EWAS studies in AD.
Integrative genetic and epigenetic analyses
Even from the restricted number of EWAS studies thus far
published, a common locus, BIN1 [26, 36], is found to
overlap with GWAS results, leading the way for integrated
analysis of genomic and epigenomic data that could essen-
tially address causality in AD (for a thorough review see
[71]). It has already been shown that genetic variants can
influence DNA methylation [72]. In this respect, application
of the Mendelian randomization (MR) method could
strengthen the causal assumption, and help in elucidating the
interplay among genetic variation, epigenetic modifications
and environmental factors. For example, with the recently
described two-step epigenetic MR method, first the causal
impact of a risk factor in an epigenetic modification is
interrogated using a genetic variant as intermediate for the
risk factor, and then the causal effect of the investigated
epigenetic change, is examined on the desired outcome (i.e.
AD) [73]. To date, EWAS data can assist identifying the risk
factor-epigenetic modification association at the first step
and GWAS data can provide the genetic variant proxy.
Interestingly, with the identification and study of methyla-
tion quantitative trait loci (mQTL) in the human brain [74], it
will be possible to trace SNPs associated with methylation at
specific genomic regions and use them as proxy [73]. An
additional integrative analysis of genomic, epigenomic and
enviromic data called longitudinal epigenome/envi-
rome/exposome-wide association study (LEWAS) was
suggested by Lahiri and Maloney [75]. The rationale of this
approach is the combination of genomic information with
repeatedly collected information of the patient’s envirome
and the epigenome [75, 76]. Therefore, changes in epige-
netic markers could be linked to the transient changes
measured prior to the clinical manifestation of a disease
[75]. All these approaches would allow the exploration of
new disease mechanisms to ultimately start to answer the
question: ‘‘Is epigenetic dysregulation a cause or conse-
quence of AD?’’ Nevertheless, at this point, it is important to
note that while the MR approach is feasible practically,
LEWAS remains a rather theoretical method due to the in-
depth interrogation of the patient’s environmental exposures
as well as the high costs it would require to conduct such a
study (reviewed by Maloney and Lahiri [76]).
One key issue that is yet to be addressed is the temporal
and spatial causality of AD pathogenesis, for example
whether the ‘‘state-of-the-art’’ technology that is being
applied in the field is being done so in relevant brain
regions at appropriate time points. Nowadays, ante-mortem
AD diagnosis is mainly based on cognitive deficits asso-
ciated with hippocampal and cortical dysfunction, as well
as with imaging studies, primarily focused on the size of
the hippocampus, which also makes these brain regions
primary targets for GWAS and EWAS studies. Despite the
catalytic involvement of hippocampal neurodegeneration
and dysfunction in the progression of the disease, it is
speculated that once the pathology has reached these
structures, the deleterious effects on brain integrity are
already irreversible [77]. Therefore, the interrogation of
(epi)genetic modifications at that stage mainly contributes
to a mechanistic understanding of the progression rather
than the cause of the disease. A full mapping of epigenetic
changes in a range of different brain structures at the
appropriate stage(s) of disease is more likely to offer
insight into the disease course, from the initial stages to the
extensive neurodegeneration of cortical and subcortical
areas. Such an approach could prompt early stage
biomarkers and novel therapeutic targets for the most
incipient stages of the disease, in addition to providing
predictive models for the expansion of the disease.
Brainstem: where it all starts?
Human AD pathology is primarily confined to the central
nervous system (CNS) [78, 79]. There, the pathology
propagates in a rather predictable, selective spatial and
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temporal manner with some regions being highly vulner-
able to the aforementioned hallmarks at specific stages and
others relatively resistant [7]. It is remarkable that the
pathology vastly targets very specific neuronal types,
which share long, late-myelinating and weakly myelinating
axons [7, 8]. Thus, the earliest detection of abnormal
hyperphosphorylated tau protein has been observed in the
brainstem, and more specifically in the magnocellular
nuclei of the basal forebrain, the raphe nuclei and the locus
coeruleus (LC) [3, 4, 7, 8, 80–104]. From there, pathology
propagates to highly vulnerable subcortical areas, i.e. the
entorhinal cortex and hippocampus, and, subsequently, to
high-order association areas of the neocortex [7, 85, 105].
Once cortical areas are affected, the curtailment of intel-
lectual functions begins, gradually leading to deterioration
or even loss of executive functions, annotating the clinical
phase of AD.
The well-orchestrated propagation of hallmarks from
subcortical to cortical regions has allowed staging of the
various preclinical and clinical phases of AD and has
facilitated the definition of neuropathological diagnostic
criteria. Among the most widely used are the modified
criteria based on NFT propagation described by Braak and
Braak [106]. The original staging scheme of 1997 included
four stages: Braak stage 0 (no NFTs); Braak stages I/II,
with NFTs amidst the (trans)entorhinal cortex area; Braak
stages III/IV, with NFTs expanding over to the hip-
pocampus and the amygdala as well as cortical areas; and
Braak stages V/VI, with pronounced NFTs over the iso-
cortex [107]. In 2011, the aforementioned scheme was
updated with the addition of the preclinical stages a–c and
1a–1b. Indicative of stages a-c is non-fibrillar abnormal tau
pathology in the brainstem, mainly becoming traceable
during teenage years [3]. Stages 1a–1b concern cases with
early abnormal tau pathology at pyramidal cells in the
transentorhinal cortex. Finally, extensive research com-
plements the Braak staging providing associations with Ab
pathology measurements as well as AD clinical assessment
tools, i.e. the mini-mental stage examination (MMSE) [7].
Increasing evidence that the brainstem may be the
starting point of the propagation of AD pathology has
triggered an ever-increasing scientific interest in the
involvement of the brainstem in AD and numerous studies
have investigated a central role of the brain serotonergic
and noradrenergic systems in its pathophysiology (re-
viewed by [7, 87, 103]). The brainstem in AD patients was
recently shown to be subjected not only to significant
volume reductions, but also structural deformations in a
magnetic resonance imaging (MRI) study [108]. Further,
the early occurrence of various non-cognitive, behavioral
and neuropsychological symptoms in AD, such as depres-
sion, general disturbances in mood, emotion, appetite,
respiratory and circadian rhythm, suggests brainstem
involvement, and more specifically that of the raphe nuclei
and the LC [3, 87, 109]. Moreover, brainstem nuclei are
affected by AD pathology, particularly tangles, in very
early, presymptomatic stages [3, 7, 87, 103, 110, 111].
Interestingly, despite their vulnerability to tau pathology,
the death of NFT-bearing neurons is not imminent during
the presymptomatic stage and even at the final stages these
neurons seem to be more resilient to degeneration
[7, 92, 99, 103, 112–115]. Nevertheless, at that time, their
function is highly impaired, impacting on the brain’s
neurochemical balance [103].
The raphe nuclei and AD
The raphe nuclei, and in particular the dorsal raphe nucleus
(DRN) contains long projecting neurons that are abundant
in serotonin (5-hydroxytryptamine; 5-HT), a monoamine
neurotransmitter synthesized out of tryptophan [116]. The
serotonergic system has been implicated in almost every
type of basic physiological behavior, including appetite,
sleep, emotional, cognitive as well as motor and neuroen-
docrine functions [116]. This widely distributed network in
the brain mainly innervates the prosencephalon, including
key areas for cognitive function, such as the frontal cortex,
hippocampus, striatum, hypothalamus and amygdala
[117, 118].
One study has found that more than 20 % of Braak stage
0 individuals and 100 % of Braak stage 1 individuals have
detectable NFTs in the DRN, indicating that the DRN is
affected by AD pathology even before the transentorhinal
cortex [119]. Accordingly, it has been suggested that the
development of pathology in the brainstem might trigger a
transneuronal spread of NFTs changes to interconnected
cortical brain areas affected at later Braak stages [110].
Even if tau ‘‘seeding’’ is still poorly understood, a sug-
gested mechanism is that, once released, intracellularly
formed tau aggregates extracellularly and is transferred to
neighboring cells, thereby inducing the production of
abnormal tau at those sites [120]. Several hypotheses on the
formation and propagation of neurotoxic Ab species have
ensued from this hypothesized ‘‘seeding’’ effect. In par-
ticular, Braak and Del Tredici suggested that Ab may
originate from projection neurons with abnormal tau within
the brainstem nuclei. Observations of accumulated toxic
Ab species in the vicinity of somatodendritic compart-
ments of neurons as well as in the terminals of their axons
in brain structures well-innervated by NFT-bearing 5-HT/
NA projections could justify the fine pattern of Ab prop-
agation and suggests that toxic Ab species are produced
and released from such projection neurons [8]. Neverthe-
less, this hypothesis remains to be tested.
The severity of AD pathology in the DRN has been
correlated not only with serotonergic denervation but
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interestingly also with behavioral changes in AD patients
[103, 104, 121]. For example, the NFT-associated lesions
that are present in the DRN even in the early phase, are
largely held responsible for explaining mood symptoms
such as depression and aggression, in prodromal AD [104].
Plaque and NFT load in the DRN and the median raphe
nuclei (MRN) of AD patients has been shown to correlate
with the progression of clinical symptoms [121, 122].
Additionally, a dysregulated serotonergic system has been
linked not only to cognitive decline, but also to distur-
bances in the circadian rhythm seen in prodromal AD
stages [123, 124].
From an anatomical point of view, post-mortem
immunohistochemically stained AD brain samples (Braak
stage V and VI) have shown a decreased number of sero-
tonergic neurons in the DRN and the MRN [103]. This
observation was recently replicated and enhanced with
correlation analysis that exhibited an age-dependent 5-HT
cell loss in particular nuclei [7, 103]. Interestingly, there
seems to be a predilection for neurodegeneration in the
caudal part of the DRN, which predominantly projects to
the septum and the hippocampal area [98, 121]. Supporting
evidence for the involvement of the 5-HT system in AD
has been provided by imaging studies. Positron emission
tomography (PET) studies have found that 5-HT1A recep-
tors were reduced in the hippocampi and raphe nuclei and
that the decrease was strongly correlated with deterioration
in the MMSE scores [125]. Moreover, while in MCI
patients a hippocampus-specific increase in 5-HT metabo-
lism and receptors (5-HT1A) has been observed, in
advanced stages of AD, serotonergic receptors are dra-
matically downregulated in cortical areas [103].
Interestingly, functional genetic coding variants in the
brain-specific tryptophan hydroxylase-2 (TPH2) and the
5-HT transporter (5-HTT) have been significantly associ-
ated with frontal lobe symptoms in AD [126].
Complementary research on the role of the serotonergic
system in AD has yielded interesting results concerning
5-HT system function and AD pathology. Preclinical
studies have demonstrated that an increase of 5-HT levels
via, e.g. pharmacological activation attenuates Ab pathol-
ogy. Both acute and chronic administration of selective
serotonin reuptake inhibitors (SSRIs) induces reduction in
the production of toxic Ab species in brains of APPswe/
PS1dE9 mice, a widely used an AD mouse model
[127, 128]. The acute administration of SSRIs is directly
impacting on Ab synthesis rather than the clearance rate of
the plaques, the main mechanism of action of the ineffec-
tive drug bapineuzumab, a humanized monoclonal
antibody targeting Ab, developed for the treatment of AD
[129]. In addition, intrahippocampal infusion of 5-HT as
well as dietary enrichment of tryptophan in the same AD
mouse model is associated with a reduction in the
formation of Ab plaques. Furthermore, treatment of non-
cognitive impaired elderly participants with SSRIs for five
consecutive years has been associated with less cortical
amyloid deposition as revealed by a positron emission
tomography (PET) study. Moreover, a reduction in the
production as well as levels of Ab was detected in the
cerebrospinal fluid (CSF) of healthy volunteers treated with
citalopram, a commonly used SSRI [128]. Finally, while
5-HT1A, 5-HT4 and 5-HT6 receptor ligands are known to
modify cognitive functions [130], they were also shown to
favor the production of non-amyloidogenic Ab precursors
that do not aggregate, with administration of 5-HT4
receptor agonists increasing the levels of soluble APP
(sAPP-a) [131].
The locus coeruleus and AD
The LC is the principal site for brain synthesis of nora-
drenaline (NA). NA is a catecholamine synthesized from
tyrosine by a series of enzymatic steps that lead to the
formation of dopamine, which is finally converted to the
final product by dopamine beta-hydroxylase (DBH) [103].
Similar to the 5-HT system, the NA system consists of long
projection neurons that are widely distributed throughout
the brain [8]. Nevertheless, patterns of regional specificity
arise as the frontal and parietal cortices are richly inner-
vated [132]. Functionally, NA has been implicated in
wakefulness and attention as well as the endocrine
response to stress, while more recent evidence has also
linked it to cognition, pain, aggression as well as energy
homeostasis and blood flow control [132].
With regard to the role of the LC in AD, Braak and
colleagues revealed that tau pathology is present in the LC
prior to any other structure and even before any clinical
symptoms or amyloid pathology manifestation was evident
[3]. Histopathological observations of the LC using post-
mortem AD brains have identified signs of atrophy,
including swollen cell bodies, contracted dendrites and
significantly decreased detection of NAergic markers
[90, 91, 103, 105, 112, 133–135]. The deformation of the
LC and the associated impairment in NA neurotransmis-
sion have been linked to the onset, severity, disease
duration, speed of cognitive decline as well as with the
appearance of AD pathology [103]. Concerning the latter,
loss of NA neurons has been associated with increased Ab
deposition as well as an increased amount of cortical NFTs,
strongly supporting the seeding-like propagation pattern
previously suggested [8].
The noradrenergic system appears to be highly dysreg-
ulated in AD. Post-mortem studies have demonstrated
reduced NA synthesis and availability in the frontal and
temporal cortex as well as in the hippocampal area
[90, 136, 137]. The rate of reduction in NA levels has been
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positively correlated with the severity of AD
[133, 136, 138, 139]. Additionally, Vermeiren and col-
leagues showed significantly decreased levels of
3-methoxy-4-hydroxyphenylglycol (MHPG), a metabolite
of NA degradation, in the prefrontal cortex of AD patients
suffering from depression [140]. Nevertheless, other stud-
ies have reported an increase in NA and MHPG plasma and
CSF levels solely in advanced AD cases [141, 142].
Another study did replicate the increased NA concentration
in the CSF but failed to detect changes in the levels of
MHPG [143]. Notably, one should be cautious interpreting
results from CSF studies to brain function, as NA normally
cannot cross the blood brain barrier (BBB), while its
metabolites like MHPG, are able to do so [144]. Thus, CSF
concentrations of MHPG reflect a sum of central and
peripheral levels and are unlikely to reflect the most con-
clusive markers of the disease progression [145].
Studies have also indicated a decrease in DBH activity
in the neocortex and the hippocampus of post-mortem
tissue from patients at early AD stages [146]. This obser-
vation has been recently replicated by Mustapic and
colleagues who additionally showed a gradual decrease in
enzymatic activity with the progression of the disease and
deterioration of cognitive functions [147]. Furthermore, the
reported decrease could explain the decreased NA levels
and the loss of noradrenergic neurons [147].
Restoration of NA levels via, e.g. exercise or pharma-
cological manipulation has shown beneficial effects on
cognition in AD. Segal and colleagues demonstrated that
exercise-mediated activation of the NAergic system can
enhance memory consolidation in MCI patients and con-
trols [148]. Moreover, administration of L-threo-
dihydroxyphenylserine (L-DOPS), a prodrug for NA,
enhances contextual and recognition memory in NA-defi-
cient mouse models. Moreover, once administered to AD
mouse models, restoration of spatial memory performance
as well as a reduction in amyloid plaque number and size in
the cortex and hippocampus were observed [149, 150].
Looking to the future
Despite the increasing interest in brainstem dysfunction in
AD, it still remains poorly understood whether the previ-
ously described structural, chemical, and functional
alterations are causally involved in the pathogenesis of AD
or whether they merely represent a consequence of the
deleterious progression of the disease, or an epiphe-
nomenon. The appearance of tau pathology with the early
non-cognitive symptomatology suggests that the brainstem
may reflect the initial structure affected by AD pathology
in the brain. Bearing in mind the functional importance of
the raphe nuclei and the LC as signaling hubs of top-down
neuromodulatory input to high-order cortical areas as well
as their vulnerability to AD neuropathology, it is tempting
to speculate that they have a crucial role in the etiopatho-
genesis of AD. Furthermore, the lack of genetic attributes
interlacing dysregulations in brainstem-specific neuro-
transmission with AD progression or pathology may
furthermore, hint at an environmental and/or epigenetic
involvement. Indeed, both the nuclei have been repeatedly
investigated as targets of epigenetic control in various
developmental stages as well as in neurological disorders.
The noradrenergic developmental genes of the LC for
instance have been reported to be under epigenetic control
suggesting the vulnerability of the nucleus to environ-
mental input [151, 152]. Moreover, it has been previously
shown that functioning of the, i.e. 5-HT system is sensitive
to gene-environment interactions (e.g. stress) [153–156].
Thus, the sensitivity of both the nuclei to environmental
stimuli and epigenetic regulation in combination with the
evidence that the brainstem is one of the first structures to
present AD pathology and that robust epigenetic changes
are seen in the latter effected cortical regions in AD offer
fertile ground for further research into studying epigenetic
dysfunction in the brainstem in the most incipient stages of
AD.
The complex and yet elusive nature of sporadic AD
allows for various hypotheses to explain the pathogenesis
of the disease. To date, none of these hypotheses have been
confirmed despite the advancements in genomic technol-
ogy that provide deeper insight into the molecular
underpinnings of AD. A possible reason is the temporal
discrepancies between the biological and the clinical onset
of the disease. Furthermore, the majority of research
studies focus on brain structures vastly associated with the
clinical phase of the disease thereby overlooking the pre-
clinical manifestations of pathology. Such studies are
invaluable in enriching the fundamental knowledge about
the pathophysiology during the progression of AD, but it is
unlikely that they will result in any of the two imperative
societal needs: early, reliable, non-invasive and inexpen-
sive biomarkers and effective treatment options that target
the disease in its most incipient stages, much earlier than
the first manifestations of cognitive curtailment.
Peripheral disease-associated epigenetic signatures have
already been successfully employed as diagnostic tools for
different cancers, and are currently being studied in neu-
rological/psychiatric disorders [157–160]. As mentioned
above, the advancements in genomic technology allows for
high throughput interrogation of the epigenome and the
extensive study of the correlation between brain and blood
epigenetic signatures will contribute to the emergence of
non-invasive and inexpensive biomarkers. Thus, epigenetic
profiling of the brainstem of (sporadic) AD patients and its
pairing with blood epigenetic signatures in the same
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individuals could potentially lead to the discovery of novel
biomarkers that are able to detect either subtle changes at
the very early stages of the disease, when the pathology is
believed to be still reversible, or even an early peripheral
response to AD pathology. Yet another exceedingly valu-
able asset of the study of epigenetic dysregulation in the
brainstem is the fact that various pharmacological inter-
ventions impacting on either the epigenetic machinery
([161]; reviewed by Maloney and Lahiri [76]) or the 5-HT/
NA system have already been developed and clinically
approved; hence they could be implemented rapidly as a
novel intervention for AD. Collectively, scrutinizing the
interactions between the early AD-affected brainstem and
the local epigenetic modifications will be of pivotal
importance not only for understanding the pathogenesis of
AD and the causal or consequential relationship of epige-
netic alterations with AD, but also for the development of
highly demanded early, reliable biomarkers and novel
therapeutic strategies.
Conclusion
The preclinical manifestations of AD, governed by non-
clinical symptoms, suggest a crucial involvement of
brainstem nuclei in the pathophysiology and most impor-
tantly in the pathogenesis of AD. Meanwhile, distinct, yet
consistent, epigenetic signatures emerging from EWAS
studies indicate a central role for the epigenetic machinery
in the progression of AD. To date, while the exponential
increase of AD-related research lines offers disparate
interpretations in the cause of AD, the lack of effective
diagnostic and/or therapeutic tools suggest that the etiology
of the disease remains shrouded. With this review, we wish
to perturb the status quo of AD, that is the genomic and
epigenomic interrogation of brain regions like the hip-
pocampus and cortex. We suggest that the temporal and
spatial manifestations of the disease should be aligned and
thus advocate that the two key nodes of the early stages of
AD should be scrutinized. The pairing of brainstem
pathology with deviant epigenetic regulation, indicative of
the incipient stages of AD pathology, could serve as
excellent candidate targets for further research that could
lead to the development on early biomarkers as well as
early treatment alternatives that could halt or even reverse
the deleterious progression of AD.
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